Department of Ophthalmology, University of Catania, Catania, Italy.
Department of Ophthalmology, Hospital of Ludwigshafen, Ludwigshafen am Rhein, Germany.
Surv Ophthalmol. 2021 May-Jun;66(3):441-460. doi: 10.1016/j.survophthal.2020.08.007. Epub 2020 Sep 10.
Radiation maculopathy and radiation-induced macular edema are common, sight-threatening complications after radiotherapy, especially that used for uveal melanoma. While many treatment and preventive strategies have been proposed, management of these conditions is still challenging. Initially, treatments were based on the use of retinal laser, but the outcomes were poor. Subsequently, management has shifted toward injection of intravitreal antivascular endothelial growth factor or corticosteroids. We reviewed current clinical evidence, which mostly relies on small sample-sized and retrospective studies, for the management of radiation maculopathy and, in particular, radiation-induced macular edema. At present, the first-line approach is usually intravitreal antivascular endothelial growth factor. Intravitreal dexamethasone implantation may be an option for those with suboptimal response or contraindications to antivascular endothelial growth factor agents. Possible preventive treatments that require future study are intravitreal bevacizumab and ranibizumab, peripheral laser photocoagulation, and subtenon triamcinolone acetonide.
放射性黄斑病变和放射性黄斑水肿是放射治疗后常见的、威胁视力的并发症,尤其是用于治疗葡萄膜黑色素瘤的放射治疗。虽然已经提出了许多治疗和预防策略,但这些疾病的治疗仍然具有挑战性。最初,治疗方法基于视网膜激光的应用,但效果不佳。随后,治疗方法转向了眼内注射抗血管内皮生长因子或皮质类固醇。我们回顾了目前的临床证据,这些证据主要依赖于小样本量和回顾性研究,用于治疗放射性黄斑病变,特别是放射性黄斑水肿。目前,一线治疗方法通常是眼内注射抗血管内皮生长因子。对于那些对治疗反应不佳或对血管内皮生长因子药物有禁忌的患者,眼内注射地塞米松植入物可能是一种选择。需要进一步研究的可能的预防治疗方法包括眼内注射贝伐单抗和雷珠单抗、周边激光光凝和曲安奈德前Tenon 注射。